In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: It is unclear whether improvement of left atrial (LA) and ventricular (LV) structure results in reduction in new-onset atrial fibrillation (AF). The aim of the present study was to examine whether changes in-treatment LA diameter were related to changes in risk of new-onset AF. METHODS: We followed 939 hypertensive patients with electrocardiographic LV hypertrophy randomized to atenolol or losartan-based regimens in the LIFE Study for a mean of 4.8 years with echocardiograms at enrolment and annually during treatment. RESULTS: New-onset AF occurred in 46 patients (10.2/1000 patient-years of follow-up). At baseline, patients with new-onset AF were older, had higher systolic blood pressure and heart rate as well as higher prevalence of LA dilatation, but had similar prevalences of LV hypertrophy and mitral or aortic valve disease. In univariate Cox analysis baseline LA diameter (HR=4.67 per cm increase [95% CI 2.86-7.65], p<0.001) and LV mass index (HR=1.11 per 10 g/m(2) increase [95% CI 1.02-1.22], p<0.05) both predicted new-onset AF. In multivariate analysis, increased baseline LA diameter increased the risk of new-onset AF (HR=5.16 per cm [95% CI 2.85-9.35], p<0.001) whereas reduction of in-treatment LA diameter reduced the risk (HR=0.21 per cm lower LA diameter during treatment [95% CI 0.14-0.32], p<0.001) with adjustment for in-treatment LV mass in-treatment systolic blood pressure, age and Framingham risk score. CONCLUSION: LA diameter at baseline and during antihypertensive treatment were equally strong predictors of new-onset AF independent of the level of arterial pressure, LV mass and other covariates. Prevention of AF during antihypertensive treatment may be improved by antihypertensive therapy that reduces LA size in addition to controlling blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826
Self-citationTsang, T. S. M., Barnes, M. E., Bailey, K. R., Leibson, C. L., Montgomery, S. C., Takemoto, Y., Diamond, P. M., Marra, M. A., Gersh, B. J., Wiebers, D. O., et al. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.5.467 · Cited by 631
Cited by
Pathak, R. K., Middeldorp, M. E., Lau, D. H., Mehta, A. B., Mahajan, R., Twomey, D., Alasady, M., Hanley, L., Antic, N. A., McEvoy, R. D., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.028 · Cited by 949
Abed, H. S., Wittert, G. A., Leong, D. P., Shirazi, M. G., Bahrami, B., Middeldorp, M. E., Lorimer, M. F., Lau, D. H., Antic, N. A., Brooks, A. G., et al. (2013) · JAMA · doi:10.1001/jama.2013.280521 · Cited by 776
Savelieva, I., Kakouros, N., Kourliouros, A., & Camm, A. J. (2011) · Europace · doi:10.1093/europace/eur002 · Cited by 312
Malmo, V., Nes, B. M., Amundsen, B. H., Tjonna, A.-E., Stoylen, A., Rossvoll, O., Wisloff, U., & Loennechen, J. P. (2016) · Circulation · doi:10.1161/circulationaha.115.018220 · Cited by 263
“This concept of AF treatment has not previously been reported, but other studies have shown that modification of risk factors reduces AF burden,(30,31) risk of new-onset AF,(32) and recurrence after ablation(33,34) and cardioversion.(32) Exercise is known to be effective in modulating cardiovascular risk factors, and…”
ResultAmat-Santos, I. J., Rodés-Cabau, J., Urena, M., DeLarochellière, R., Doyle, D., Bagur, R., Villeneuve, J., Côté, M., Nombela-Franco, L., Philippon, F., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.061 · Cited by 259
Metadata
- Authors
- Wachtell, K., Gerdts, E., Aurigemma, G. P., Boman, K., Dahlöf, B., Nieminen, M. S., Olsen, M. H., Okin, P. M., Palmieri, V., Rokkedal, J. E., & Devereux, R. B.
- Venue
- Blood Pressure
- Publisher
- Informa UK Limited
- Published
- 2010-01
- Volume
- 19
- Issue
- 3
- Pages
- 169-175
- ISSN
- 0803-7051 (ISSN-L)
- 1651-1999
- OpenAlex
- W2073719227
- Cited by
- 67
- References
- 4
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. https://app.cochat.ai/papers/10.3109/08037051.2010.481811
- The paper
- Wachtell, K., Gerdts, E., Aurigemma, G. P., Boman, K., Dahlöf, B., Nieminen, M. S., Olsen, M. H., Okin, P. M., Palmieri, V., Rokkedal, J. E., & Devereux, R. B. (2010). In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Pressure. https://doi.org/10.3109/08037051.2010.481811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.